3Kayaselcuk F,Zorludemir S,Gumurdulu D,et al.PCNA and Ki-67 in central nervous system tumors:correclation with the histological and grade.J Neurooncol,2002;57:115～121
4Reavey-Cantwell JF,Haroun RI,Zahurak M,et al.The prognostic value of tumor markers in patients with glioblastoma multiforme:analysis of 32 patients and review of the literature.J Neurooncol,2001;55:195～204
5Huang FH,Kanno HS,Yamamotol I,et al.Correlation of clinical features and telomerase activity in human gliomas.J Neurooncol,1999;43:137～142
6Falchetti ML,Pallini R,Larocca LM,et al.Telomerase expression in intracranial tumours:prognostic potential for malignant gliomas and meningiomas.J Clin Pathol,1999;52:234～236
7Iny V,Edwards V,Halliday W,et al."Ployphenotypic" tumors in the central nervous system:problems in nosology and classification.Pedictr Pathol Lab Med,1997;17(3):369～389
8Maity A,Pore N,Lee J,et al.Epidermal growth factor recepor transcriptionally upregulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway in-kinase and distinct from that volving phoshatidylinositol3*induced by hypoxial.Cancer Res,2000;60:5879～5886
9Jin W,Xu X,Yang T,et al.p53 mutation,EGGR gene amplification and loss of heterozygosity on chromosome 10,17p in human gliomas.Chin Med J(Engl),2000;113(7):662～666
10Schiebe M,Ohneseit P,Hoffmann W,et al.Loss of heterozygosity at 1 1p15 and p53 alterations in malignant gliomas.J Cancer Res Clin Oncol,2001;127(5):325～328
